Listed

CytoDyn Inc.: Form 10-Q for the period ended Aug 31, 2023

Filed with the SEC on Oct 23, 2023 and accepted by EDGAR at Oct 23, 2023, 21:16 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-08-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2023-06-01 to 2023-08-31$1.9mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2023-06-01 to 2023-08-31−$4.6mus-gaap:OperatingIncomeLoss
Income tax3 months2023-06-01 to 2023-08-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-06-01 to 2023-08-31−$11.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-06-01 to 2023-08-31−$0.01us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-06-01 to 2023-08-31−$0.01us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-06-01 to 2023-08-31923,587,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2023-06-01 to 2023-08-31−$4.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2023-08-31$2.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-08-31$12.0mus-gaap:AssetsCurrent
Total assetsAt period end2023-08-31$12.4mus-gaap:Assets
Current liabilitiesAt period end2023-08-31$129.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-08-31$129.3mus-gaap:Liabilities
Long-term debtAt period end2023-08-31$44.9mus-gaap:LongTermDebt
Shareholders' equityAt period end2023-08-31−$116.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-23-016632. Last ingested by Listed: Oct 24, 2026, 14:53 ET. Listed shows no prices and gives no investment advice.